Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Mantle Cell Lymphoma Mantle Cell Lymphoma for November/December 2019 Some MCL patients can safely stop venetoclax-ibrutinib, study suggests, KTE-X19 produces highest response rate in MCL subgroup, Orelabrutinib Could be ‘Preferred’ BTK Inhibitor for MCL, SOX11 Shows Value as Diagnostic Marker in MCL, Acalabrutinib may Outperform Other Targeted Therapies in MCL, More must reads Mantle Cell Lymphoma for September/October 2019 Follow-Up Shows Favorable Results With Acalabrutinib in MCL, Staging PET/CT Better Defines Extent of Mantle Cell Lymphoma, Rituximab, Bendamustine Look Better Than Chemo Alone in MCL, More must readsMantle Cell Lymphoma for July/August 2019 Ibrutinib-Rituximab Induction Yields ‘Unprecedented’ Responses in MCL, Ibrutinib/Rituximab Effective, Safe as Frontline Treatment for Older Patients With MCL, Low-Dose Radiation Therapy Looks Effective in Hard-to-Treat MCL, Flavopiridol Elicits Poor Response in Mantle Cell Lymphoma, DLBCL, More must readsMantle Cell Lymphoma for May/June 2019 Obinutuzumab provides strong early responses in untreated MCL, CD23 expression linked to improved survival in MCL, More must readsMantle Cell Lymphoma for March/April 2019 RIT consolidation may be an option for unfit MCL patients, Early data support R-BAC for post-BTKi mantle cell lymphoma, MCL Survival Rates Improve With Novel Agents, Worse Survival Seen Among Black Patients With MCL, Bendamustine-Rituximab Shines in Frontline Treatment of MCL, iNHL, More must readsPages1 2 3 4 next › last »
